Literature DB >> 23256168

Synthesis, grading, and presentation of evidence in guidelines: article 7 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.

Gordon Guyatt, Elie A Akl, Andy Oxman, Kevin Wilson, Milo A Puhan, Timothy Wilt, David Gutterman, Mark Woodhead, Elliott M Antman, Holger J Schünemann.   

Abstract

INTRODUCTION: Professional societies, like many other organizations around the world, have recognized the need to use more rigorous processes to ensure that health care recommendations are informed by the best available research evidence. This is the seventh of a series of 14 articles that were prepared to advise guideline developers in respiratory and other diseases on approaches for guideline development. This article focuses on synthesizing, rating, and presenting evidence in guidelines.
METHODS: In this review we addressed the following questions. (1) What evidence should guideline panels use to inform their recommendations? (2) How should they rate the quality of the evidence they use? (3) How should they grade evidence regarding diagnostic tests? (4) What should they do when quality of evidence differs across outcomes? (5) How should they present the evidence in a guideline? We did not conduct systematic reviews ourselves. We relied on prior evaluations of electronic databases and systematic reviews suggesting that the Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) approach includes the desired features of a system for grading quality of evidence, including provision of models for presenting evidence for guideline panels, and for the consumers of practice guidelines. This article describes the GRADE approach to grading the quality of evidence and presenting evidence. Available evidence, the practice of leading guideline developers, and workshop discussions provide the basis for our conclusions. RESULTS AND DISCUSSION: GRADE rates the quality of evidence for each outcome across studies rather than for each study. In the GRADE approach randomized trials start as high-quality evidence and observational studies as low-quality evidence, but both can be rated down or up. Five factors may lead to rating down the quality of evidence: study limitations or risk of bias, inconsistency of results, indirectness of evidence, imprecision, and publication bias. Three factors may lead to rating up the quality of evidence from observational studies: large magnitude of effect, dose-response gradient, and situations in which all plausible confounders would decrease an apparent treatment effect, or would create a spurious effect when results suggest no effect. GRADE suggests use of evidence profiles that provide a comprehensive way to display the key evidence relevant to a clinical question. Guideline developers who follow this structure will find the transparency of their recommendations markedly enhanced.

Mesh:

Year:  2012        PMID: 23256168     DOI: 10.1513/pats.201208-060ST

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  6 in total

1.  A Comparative Analysis of Pulmonary and Critical Care Medicine Guideline Development Methodologies.

Authors:  Noah C Schoenberg; Alan F Barker; John Bernardo; Robin R Deterding; Jerrold J Ellner; Dean R Hess; Neil R MacIntyre; Fernando J Martinez; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

2.  Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise.

Authors:  Holger J Schünemann; Wojtek Wiercioch; Itziar Etxeandia; Maicon Falavigna; Nancy Santesso; Reem Mustafa; Matthew Ventresca; Romina Brignardello-Petersen; Kaja-Triin Laisaar; Sérgio Kowalski; Tejan Baldeh; Yuan Zhang; Ulla Raid; Ignacio Neumann; Susan L Norris; Judith Thornton; Robin Harbour; Shaun Treweek; Gordon Guyatt; Pablo Alonso-Coello; Marge Reinap; Jan Brozek; Andrew Oxman; Elie A Akl
Journal:  CMAJ       Date:  2013-12-16       Impact factor: 8.262

Review 3.  Stem Cell-Based Therapy for Experimental Ischemic Stroke: A Preclinical Systematic Review.

Authors:  Xi-Le Zhang; Xiao-Guang Zhang; Yan-Ran Huang; Yan-Yan Zheng; Peng-Jie Ying; Xiao-Jie Zhang; Xiao Lu; Yi-Jing Wang; Guo-Qing Zheng
Journal:  Front Cell Neurosci       Date:  2021-04-14       Impact factor: 5.505

4.  Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?

Authors:  Bram Rochwerg; Holger J Schünemann; Ganesh Raghu
Journal:  BMC Med       Date:  2016-02-10       Impact factor: 8.775

5.  Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

Authors:  Nicolas Roche; Jonathan D Campbell; Jerry A Krishnan; Guy Brusselle; Alison Chisholm; Leif Bjermer; Mike Thomas; Eric van Ganse; Maarten van den Berge; George Christoff; Jennifer Quint; Nikolaos G Papadopoulos; David Price
Journal:  Clin Transl Allergy       Date:  2019-03-27       Impact factor: 5.871

6.  Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement.

Authors:  Andrea S Gershon; Peter K Lindenauer; Kevin C Wilson; Louise Rose; Allan J Walkey; Mohsen Sadatsafavi; Kevin J Anstrom; David H Au; Bruce G Bender; M Alan Brookhart; Raed A Dweik; MeiLan K Han; Min J Joo; Valery Lavergne; Anuj B Mehta; Marc Miravitlles; Richard A Mularski; Nicolas Roche; Eyal Oren; Kristin A Riekert; Noah C Schoenberg; Therese A Stukel; Curtis H Weiss; Hannah Wunsch; Joel J Africk; Jerry A Krishnan
Journal:  Am J Respir Crit Care Med       Date:  2021-01-01       Impact factor: 21.405

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.